KYNTRA BIO, INC. (KYNB) Stock Profile — Insider Trades & Financials

Revenue$1.3M

Net Income-$14.2M

EPS$45.37

Market Cap$28.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Thane Wettig

CEO & Executive Director

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.

Founded: 1993
Employees: 52
Headquarters: SAN FRANCISCO, CA, United States
Website

⚡

Core Efficiency

ROE?

47.34%

ROA?

-11.89%

D/E Ratio?

-3.83

Op. Margin?

-1058.10%

📊

Profitability Ratios

Net Margin?

-1113.55%

Loading company sections...

KYNTRA BIO, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness